No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AORT Artivion
- 28.010
- +0.120+0.43%
Close Jul 24 16:00 ET
1.17BMarket Cap-116708P/E (TTM)
28.460High27.620Low220.39KVolume27.710Open27.890Pre Close6.19MTurnover0.64%Turnover RatioLossP/E (Static)41.73MShares29.24052wk High3.96P/B964.04MFloat Cap12.15852wk Low--Dividend TTM34.42MShs Float42.745Historical High--Div YieldTTM3.01%Amplitude1.335Historical Low28.108Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
A Glimpse Into The Expert Outlook On Artivion Through 4 Analysts
Artivion Is Maintained at Buy by Lake Street
Artivion Analyst Ratings
Lake Street Maintains Artivion(AORT.US) With Buy Rating, Raises Target Price to $30
Artivion's Strong Market Position and Revised Endospan Deal Justify a Buy Rating and Increased Price Target
Express News | Endospan Announces Agreement With Artivion For Additional Loans Up To $25M To Support FDA Approval Of NEXUS Stent Graft System
Comments
Artivion's management optimizes capital structure for a new phase of profitable growth. Strong conviction in business outlook, recent financial performance and clinical data readouts expected to deliver significant shareholder value.
Press Release: Artivion Obtains $350 Million in Senior Secured Credit FacilitiesArtivion's reinvestment has not significantly improved sales, resulting in a 52% decline in stock over the past five years. The market perspective shows skepticism, implying Artivion may not have substantial growth potential.
Gapping up
In reaction to earnings/guidance:
• $CalAmp(CAMP.US$ +0.6%
Other news:
• $Cano Health(CANO.US$ +6.1% ( $Humana(HUM.US$ in the running to acquire CANO according to WSJ)
• $Corcept Therapeutics(CORT.US$ +4.5% (extends deal with Optime Care to March 31 2024)
• $LPL Financial(LPLA.US$ +4.1% (reports monthly activity for August)
• $Dentsply Sirona(XRAY.US$ +3% (names new CFO)
• $iPath Series B S&P 500 VIX Short-Term Futures ETN(VXX.US$ +2.9% (tr...
In reaction to earnings/guidance:
• $CalAmp(CAMP.US$ +0.6%
Other news:
• $Cano Health(CANO.US$ +6.1% ( $Humana(HUM.US$ in the running to acquire CANO according to WSJ)
• $Corcept Therapeutics(CORT.US$ +4.5% (extends deal with Optime Care to March 31 2024)
• $LPL Financial(LPLA.US$ +4.1% (reports monthly activity for August)
• $Dentsply Sirona(XRAY.US$ +3% (names new CFO)
• $iPath Series B S&P 500 VIX Short-Term Futures ETN(VXX.US$ +2.9% (tr...
16
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg